Presentation is loading. Please wait.

Presentation is loading. Please wait.

Predicted pathogenic BRCA1 amino acid substitutions are confined to the evolutionarily conserved N- and C-terminal domains. Predicted pathogenic BRCA1.

Published byJulius Dixon Modified over 4 years ago

Similar presentations

Presentation on theme: "Predicted pathogenic BRCA1 amino acid substitutions are confined to the evolutionarily conserved N- and C-terminal domains. Predicted pathogenic BRCA1."— Presentation transcript:

1 Predicted pathogenic BRCA1 amino acid substitutions are confined to the evolutionarily conserved N- and C-terminal domains. Predicted pathogenic BRCA1 amino acid substitutions are confined to the evolutionarily conserved N- and C-terminal domains. Schematic representation of the BRCA1 protein with the positions of variants classified as neutral (green) or deleterious (red) indicated. Positive and negative controls are depicted by open pinheads and the known deleterious truncation mutations 185delAG (N-terminal) and 5382insC (C-terminal) are marked in blue. The amino acid sequences of the evolutionarily conserved RING (N-terminal) and BRCT (C-terminal) domains are specified to show the exact positions of deleterious (red) and neutral (green) variants. The amino acid substitutions or nonsense (X) mutations of positive and negative controls are encircled. Peter Bouwman et al. Cancer Discovery 2013;3: ©2013 by American Association for Cancer Research

Download ppt "Predicted pathogenic BRCA1 amino acid substitutions are confined to the evolutionarily conserved N- and C-terminal domains. Predicted pathogenic BRCA1."

Similar presentations

What exactly is a mutated gene? Nope, that’s not it.

What exactly is a mutated gene? Nope, that’s not it.
Positive Negative Tanz et al. Supp Fig. 1 unassigned st r . . & env.

Positive Negative Tanz et al. Supp Fig. 1 unassigned st r . . & env.
TRKA oncogenic variants and TRK gene fusion partners.

TRKA oncogenic variants and TRK gene fusion partners.
The cBio Cancer Genomics Portal.

The cBio Cancer Genomics Portal.
Figure 2 Sanger sequencing, conservation, and summary of known ACO2 mutations Sanger sequencing, conservation, and summary of known ACO2 mutations (A)

Figure 2 Sanger sequencing, conservation, and summary of known ACO2 mutations Sanger sequencing, conservation, and summary of known ACO2 mutations (A)
“Ring-Fencing” BRCA1 Tumor Suppressor Activity

“Ring-Fencing” BRCA1 Tumor Suppressor Activity
Representation of the 15 selected premature termination codons (PTCs) and their corresponding recoded major protein. Representation of the 15 selected.

Representation of the 15 selected premature termination codons (PTCs) and their corresponding recoded major protein. Representation of the 15 selected.
Phosphorylation and sequence disorder in microtubule-associated protein Tau.A, schematic illustration of the domain profile of Tau with all known phosphorylation.

Phosphorylation and sequence disorder in microtubule-associated protein Tau.A, schematic illustration of the domain profile of Tau with all known phosphorylation.
Sequence analyses and evolutionary conservation of the CLDN10 gene and the identified CLDN10 variants. Sequence analyses and evolutionary conservation.

Sequence analyses and evolutionary conservation of the CLDN10 gene and the identified CLDN10 variants. Sequence analyses and evolutionary conservation.
The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the Rh D-negative blood group phenotype.

The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the Rh D-negative blood group phenotype.
Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.

Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.
VWF sequence variants: innocent until proven guilty

VWF sequence variants: innocent until proven guilty
Multiple sequence alignment and analysis of SOFL proteins.

Multiple sequence alignment and analysis of SOFL proteins.
“Ring-Fencing” BRCA1 Tumor Suppressor Activity

“Ring-Fencing” BRCA1 Tumor Suppressor Activity
Extension of the GlyRβ binding site on gephyrin.

Extension of the GlyRβ binding site on gephyrin.
Figure 1. Type and distribution within KCNQ2 protein of variants in self-limiting epilepsy vs epileptic encephalopathy Type and distribution within KCNQ2.

Figure 1. Type and distribution within KCNQ2 protein of variants in self-limiting epilepsy vs epileptic encephalopathy Type and distribution within KCNQ2.
Transcriptional activities of c-MYB and A-MYB fusion proteins.

Transcriptional activities of c-MYB and A-MYB fusion proteins.
Fig. 3. Structure of ALS-associated RNA binding proteins.

Fig. 3. Structure of ALS-associated RNA binding proteins.
Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.
A: OAZ1 mRNA transcript of 775-1, and parental cell lines showing the stop codon introduced by the nonsense mutations in the and transcripts,

A: OAZ1 mRNA transcript of 775-1, and parental cell lines showing the stop codon introduced by the nonsense mutations in the and transcripts,

Similar presentations

Ads by Google